Natixis’s Teladoc Health TDOC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-94,400
Closed -$661K 1319
2025
Q4
$661K Buy
+94,400
New +$739K ﹤0.01% 793
2025
Q1
Sell
-425
Closed -$3.86K 1188
2024
Q4
$3.86K Hold
425
﹤0.01% 979
2024
Q3
$3.9K Buy
425
+27
+7% +$223 ﹤0.01% 877
2024
Q2
$3.89K Sell
398
-19,500
-98% -$238K ﹤0.01% 916
2024
Q1
$300K Buy
+19,898
New +$361K ﹤0.01% 676
2023
Q3
Sell
-120,200
Closed -$3.04M 1136
2023
Q2
$3.04M Buy
120,200
+99,748
+488% +$2.51M 0.02% 360
2023
Q1
$530K Sell
20,452
-8,314
-29% -$222K ﹤0.01% 607
2022
Q4
$680K Sell
28,766
-623,053
-96% -$16.8M ﹤0.01% 681
2022
Q3
$16.6M Buy
651,819
+503,193
+339% +$17.7M 0.08% 190
2022
Q2
$4.93M Sell
148,626
-234,800
-61% -$9.97M 0.02% 451
2022
Q1
$27.7M Buy
383,426
+7,028
+2% +$506K 0.1% 204
2021
Q4
$34.6M Sell
376,398
-66,849
-15% -$7.99M 0.12% 154
2021
Q3
$56.2M Buy
+443,247
New +$64.5M 0.19% 102
2021
Q2
Sell
-289,287
Closed -$52.6M 1021
2021
Q1
$52.6M Buy
289,287
+57,953
+25% +$13.4M 0.17% 122
2020
Q4
$46.3M Buy
231,334
+56,667
+32% +$11.5M 0.17% 124
2020
Q3
$38.3M Buy
174,667
+128,658
+280% +$27.2M 0.28% 91
2020
Q2
$8.78M Sell
46,009
-31
-0.1% -$5.43K 0.07% 206
2020
Q1
$7.14M Sell
46,040
-686
-1% -$79.8K 0.06% 232
2019
Q4
$3.89M Buy
46,726
+430
+0.9% +$32.7K 0.02% 450
2019
Q3
$3.13M Buy
46,296
+34,030
+277% +$2.24M 0.02% 429
2019
Q2
$815K Sell
12,266
-11,943
-49% -$696K 0.01% 563
2019
Q1
$1.3M Sell
24,209
-2,006
-8% -$122K 0.01% 545
2018
Q4
$1.3M Buy
26,215
+4,363
+20% +$267K 0.01% 476
2018
Q3
$1.89M Buy
+21,852
New +$1.56M 0.01% 488
2017
Q4
Sell
-6,693
Closed -$222K 1158
2017
Q3
$222K Buy
+6,693
New +$219K ﹤0.01% 1074

Other funds holding TDOC

Natixis's TDOC Position: Q1 2026 in Review

Natixis sold out of Teladoc Health (TDOC) in Q1 2026, closing a stake of 94,400 shares — an estimated $661K sold.

Natixis first reported a position in TDOC in Q3 2017 and held it in 25 quarters. The position peaked at $56.2M in Q3 2021. 324 funds tracked by Wall St. Rank hold TDOC as of Q1 2026.

  • Natixis reported no remaining Teladoc Health position as of Q1 2026 after selling out during the quarter.
  • Natixis sold 94,400 Teladoc Health shares in Q1 2026, an estimated $661K.
  • Natixis first reported a position in Teladoc Health in Q3 2017 and held it in 25 quarters.
  • Natixis's Teladoc Health position peaked at $56.2M in Q3 2021.
  • 324 funds tracked by Wall St. Rank held Teladoc Health as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.